Logo 1.png
Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights
August 03, 2022 17:30 ET | Aeterna Zentaris Inc
– Company ended the quarter with $58.2 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE...
Zhittya Logo.jpg
Zhittya Genesis Medicine announces: Free Zoom Webinar: Parkinson’s Disease Sufferers Motor Skills Improve by 50% After Medical Research Study
June 21, 2022 10:00 ET | Zhittya Genesis Medicine Inc
LAS VEGAS, June 21, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that they will be hosting a webinar on June 23, 2022 at 3:00 PM Pacific Time...
Zhittya Logo.jpg
Zhittya Genesis Medicine Announces: Parkinson’s Disease Sufferers Motor Skills Improved by 50% After Medical Research Study
June 16, 2022 14:00 ET | Zhittya Genesis Medicine Inc
LAS VEGAS, June 16, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that the human test subjects in its first-in-human research study for the...
Parkinson's Foundation Appoints Utah Tech CEO Cory Pinegar as President and Board Member of Newly Formed Rocky Mountain Chapter Board of Advisors
June 08, 2022 12:15 ET | The Parkinson's Foundation
SALT LAKE CITY, June 08, 2022 (GLOBE NEWSWIRE) -- The Parkinson's Foundation has named visionary entrepreneur Cory Pinegar as President of the Rocky Mountain Chapter Board of Advisors and Board...
Zhittya Logo.jpg
Zhittya Genesis Medicine Completes its First-In-Human Study with a Novel Intranasal Treatment for Parkinson’s Disease
June 08, 2022 11:00 ET | Zhittya Genesis Medicine Inc
LAS VEGAS, June 08, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that it has completed its first-in-human research study for the treatment of...
Denali_T_Logo_02.jpg
Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease
May 31, 2022 08:00 ET | Denali Therapeutics Inc.
BIIB122 is an inhibitor of LRRK2, a potential novel target intended to impact the underlying biology and slow the progression of Parkinson’s diseasePhase 2b LUMA to enroll approximately 640...
Straits Research Pvt Ltd
Neurodegenerative Diseases Market to reach USD 53 Billion by 2030 and grow steadily at a CAGR of 3.2%: Straits Research
May 27, 2022 11:30 ET | Straits Research
New York, United States, May 27, 2022 (GLOBE NEWSWIRE) -- Neurodegenerative diseases are a large and diverse group of disorders characterized by progressive deterioration of the function and...
gainlogo.png
Gain Therapeutics Presents Positive Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at the 2022 Synuclein Meeting
April 12, 2022 13:00 ET | Gain Therapeutics, Inc.
BETHESDA, Md., April 12, 2022 (GLOBE NEWSWIRE) --  Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted...
Cutting-Edge Research Reveals Greater Insights into Parkinson’s Disease Progression
April 11, 2022 13:41 ET | Clinical Ink
Horsham, PA, April 11, 2022 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, today—World Parkinson’s Day—announces research that strengthens its standing as a critical...
A Non-Invasive Digital Therapeutic, JOGO-Gx, Shows Early Success in Treating Parkinson's Disease Symptoms
March 17, 2022 09:00 ET | JOGO Health
BRIDGEWATER, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- JOGO-Gx, a non-invasive digital therapeutic built with AI and wearables that taps into the neuroplasticity of the brain using biofeedback, shows...